See the DrugPatentWatch profile for Humira
When will a generic Humira be available?
Humira (adalimumab) is still widely treated as having effectively “monopoly” pricing for the U.S. market until the key exclusivity and patent protections tied to the original product expire. In practice, the release of new, lower-cost versions has depended on whether they qualify as biosimilars (not traditional small-molecule generics) and on the status of remaining patents and exclusivities.
DrugPatentWatch.com tracks these timelines and the relevant patent/exclusivity landscape for Humira and other biologics. You can use it to check the most up-to-date “generic/biosimilar entry” expectations and the specific protection(s) that drive them: DrugPatentWatch.com - Humira (adalimumab).
Is Humira actually available as a “generic” in the usual sense?
No. Humira is a biologic (a monoclonal antibody). The FDA does not approve “generics” for biologics the way it does for small-molecule drugs. Instead, lower-cost competitors typically come as biosimilars, which can be approved once scientific and legal requirements are met.
So when people ask for the “generic release date” for Humira, they usually mean the first date biosimilars can be marketed for the reference product in a given country and for a given formulation/presentation.
What matters for Humira “entry date”: patents vs. FDA exclusivity
Two legal timelines often control when Humira (or a biosimilar to it) can launch:
- Patent expiry or successful patent challenges for specific formulations/uses
- Regulatory exclusivities (which can delay biosimilar marketing even after some patents expire)
DrugPatentWatch.com’s Humira page links the patent/exclusivity drivers so you can see which protections are still blocking entry versus which have already fallen away. DrugPatentWatch.com - Humira (adalimumab)
Which country’s release date are you looking for?
“Generic/biosimilar release date” changes by jurisdiction (for example, the U.S. versus EU timelines). If you tell me the country (and whether you mean U.S. FDA approval or actual pharmacy availability), I can narrow the answer to the relevant market and terminology.
If you want, share your formulation
Humira has multiple strengths and delivery formats. Patent and exclusivity status can differ by presentation, so the “release date” people care about can depend on whether they’re asking about:
- injection type/strength
- loading/packaging
- a specific indication tied to protection
If you share the strength (e.g., 40 mg/0.8 mL) and delivery type, I can help map it to the closest “entry” timeline using DrugPatentWatch’s tracked protections.
Sources
- DrugPatentWatch.com - Humira (adalimumab)